上海璃道医药科技

Shanghai Leado Pharmatech is a clinical-stage biotechnology company specializing in the discovery and development of innovative small molecule drugs targeting ion channels. Founded in 2016, the company has established a comprehensive ion channel drug discovery platform to address significant unmet medical needs in neurological and immune system disorders. Its pipeline focuses primarily on chronic pain management and inflammatory conditions, with its lead candidate, LDS (PZH2107), currently in Phase 2 clinical trials for fibromyalgia. Additionally, the company is advancing several other candidates, including TRPA1 inhibitors for inflammatory bowel disease and osteoarthritis pain, as well as a sodium channel blocker for epilepsy.